BRPI0112115B8 - compostos moduladores ppar-gamma de quinolinil e benzotiazolil - Google Patents

compostos moduladores ppar-gamma de quinolinil e benzotiazolil

Info

Publication number
BRPI0112115B8
BRPI0112115B8 BRPI0112115A BR0112115A BRPI0112115B8 BR PI0112115 B8 BRPI0112115 B8 BR PI0112115B8 BR PI0112115 A BRPI0112115 A BR PI0112115A BR 0112115 A BR0112115 A BR 0112115A BR PI0112115 B8 BRPI0112115 B8 BR PI0112115B8
Authority
BR
Brazil
Prior art keywords
ppar
benzothiazolyl
quinolinyl
compounds
substituted
Prior art date
Application number
BRPI0112115A
Other languages
English (en)
Other versions
BR0112115A (pt
BRPI0112115B1 (pt
Inventor
Hagiwara Atsushi
Shinkai Hisashi
B Houze Jonathan
R Mcgee Lawrence
Furukawa Noboru
M Rubenstein Steven
Original Assignee
Japan Tobacco Inc
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc, Tularik Inc filed Critical Japan Tobacco Inc
Publication of BR0112115A publication Critical patent/BR0112115A/pt
Publication of BRPI0112115B1 publication Critical patent/BRPI0112115B1/pt
Publication of BRPI0112115B8 publication Critical patent/BRPI0112115B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Holo Graphy (AREA)
  • Quinoline Compounds (AREA)

Abstract

"compostos moduladores ppar-gamma de quinolinil e benzotiazolil". compostos que têm a fórmula (i) onde ar^ 1^ é 2-benzotiazolil substituído ou não-substituído ou quinolinil substituído ou não-substituído; x é -o-, -c (o)-, -ch (r^ 10^) -, n (r^ 11^)-, ou -s (o)~ k~; y é n (r^ 12^) -s- (o)~ 2~-; r^ 1^ é hidrogênio ou um substituinte especificado; r^ 2^ é aril substituído ou não-substituído; e r^ 3^ é halogênio ou (c~ 1~ -c~ 8~) alcoxi são úteis no tratamento ou prevenção de uma condição ou distúrbio mediado por ppar<sym>. em particular, os compostos da invenção modulam a função de ppar<sym>. os métodos em questão são particularmente úteis no tratamento e/ou prevenção de diabetes, obesidade, hipercolesterolemia, artrite reumatóide e aterosclerose.
BRPI0112115A 2000-06-28 2001-06-27 compostos moduladores ppar-gamma de quinolinil e benzotiazolil BRPI0112115B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21481000P 2000-06-28 2000-06-28
PCT/US2001/020756 WO2002000633A1 (en) 2000-06-28 2001-06-27 Quinolinyl and benzothiazolyl ppar-gamma modulators

Publications (3)

Publication Number Publication Date
BR0112115A BR0112115A (pt) 2003-04-29
BRPI0112115B1 BRPI0112115B1 (pt) 2016-07-26
BRPI0112115B8 true BRPI0112115B8 (pt) 2021-05-25

Family

ID=22800496

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0112115A BRPI0112115B8 (pt) 2000-06-28 2001-06-27 compostos moduladores ppar-gamma de quinolinil e benzotiazolil

Country Status (25)

Country Link
EP (1) EP1296967B1 (pt)
JP (1) JP4515026B2 (pt)
KR (1) KR100771286B1 (pt)
CN (1) CN1243741C (pt)
AT (1) ATE327984T1 (pt)
AU (2) AU7163701A (pt)
BR (1) BRPI0112115B8 (pt)
CA (1) CA2412723C (pt)
CY (1) CY1105126T1 (pt)
CZ (1) CZ302982B6 (pt)
DE (1) DE60120163T2 (pt)
DK (1) DK1296967T3 (pt)
EA (1) EA005976B1 (pt)
ES (1) ES2265435T3 (pt)
HK (1) HK1052351B (pt)
HU (1) HUP0301482A3 (pt)
IL (2) IL153461A0 (pt)
MX (1) MXPA02012708A (pt)
NO (1) NO325448B1 (pt)
NZ (1) NZ523229A (pt)
PL (1) PL214670B1 (pt)
PT (1) PT1296967E (pt)
SK (1) SK288236B6 (pt)
WO (1) WO2002000633A1 (pt)
ZA (1) ZA200210283B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US6653332B2 (en) 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
WO2003024395A2 (en) 2001-09-14 2003-03-27 Tularik Inc. Linked biaryl compounds
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
CA2784937A1 (en) 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
EP1798223B2 (en) 2002-11-18 2014-07-30 ChemoCentryx, Inc. Aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
PL377712A1 (pl) 2003-02-13 2006-02-06 Wellstat Therapeutics Corporation Związki do leczenia zaburzeń metabolicznych
AU2004229467B2 (en) * 2003-04-11 2007-01-25 The University Of Tennessee Research Foundation Lysophosphatidic acid analogs and inhibition of neointima formation
EP1630152A4 (en) * 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
EP1786782B1 (en) * 2004-08-12 2010-03-31 Amgen Inc. Bisaryl-sulfonamides
CN101374414A (zh) 2006-01-25 2009-02-25 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
WO2007087505A2 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR20080097418A (ko) 2006-02-02 2008-11-05 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물
CA2641673A1 (en) * 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
PT2094663E (pt) * 2006-09-21 2011-04-19 Piramal Life Sciences Ltd Derivados de piridina para o tratamento de desordens metabólicas relacionadas com resistência à insulina ou hiperglicemia
WO2012162463A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Benzothiazolyl inhibitors of pro-matrix metalloproteinase activation
MX2017011586A (es) 2015-03-09 2017-10-26 Intekrin Therapeutics Inc Metodos para el tratamiento de enfermedad de higado graso no alcoholico y/o lipodistrofia.
MX2019011867A (es) 2017-04-03 2020-01-09 Coherus Biosciences Inc Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva.
CN109651208B (zh) * 2017-10-10 2022-01-04 中国科学院上海药物研究所 N-芳基磺酰胺类化合物，其药物组合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3632329A1 (de) * 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
EP1053227B1 (en) * 1998-01-29 2008-11-05 Amgen Inc. Ppar-gamma modulators
NZ530833A (en) * 1999-06-30 2005-08-26 Tularik Inc Compounds for the modulation of PPARgamma activity

Also Published As

Publication number Publication date
SK288236B6 (sk) 2015-01-07
ES2265435T3 (es) 2007-02-16
MXPA02012708A (es) 2003-09-22
EA200300078A1 (ru) 2003-08-28
BR0112115A (pt) 2003-04-29
WO2002000633A1 (en) 2002-01-03
JP2004501905A (ja) 2004-01-22
AU2001271637B2 (en) 2006-05-04
SK18352002A3 (sk) 2003-04-01
NZ523229A (en) 2004-10-29
ZA200210283B (en) 2005-09-28
EP1296967B1 (en) 2006-05-31
AU7163701A (en) 2002-01-08
HK1052351B (zh) 2006-11-03
CN1243741C (zh) 2006-03-01
IL153461A0 (en) 2003-07-06
EA005976B1 (ru) 2005-08-25
CA2412723C (en) 2010-12-14
CZ20024197A3 (cs) 2003-06-18
NO20026156D0 (no) 2002-12-20
CN1438998A (zh) 2003-08-27
KR100771286B1 (ko) 2007-10-29
HUP0301482A3 (en) 2005-12-28
CZ302982B6 (cs) 2012-02-01
DE60120163T2 (de) 2007-04-12
EP1296967A1 (en) 2003-04-02
DK1296967T3 (da) 2006-10-02
PT1296967E (pt) 2006-10-31
IL153461A (en) 2007-10-31
CY1105126T1 (el) 2010-03-03
HUP0301482A2 (hu) 2003-09-29
KR20030024713A (ko) 2003-03-26
BRPI0112115B1 (pt) 2016-07-26
ATE327984T1 (de) 2006-06-15
CA2412723A1 (en) 2002-01-03
NO20026156L (no) 2003-02-25
DE60120163D1 (de) 2006-07-06
PL214670B1 (pl) 2013-08-30
HK1052351A1 (en) 2003-09-11
JP4515026B2 (ja) 2010-07-28
PL359996A1 (en) 2004-09-06
NO325448B1 (no) 2008-05-05

Similar Documents

Publication Publication Date Title
BRPI0112115B8 (pt) compostos moduladores ppar-gamma de quinolinil e benzotiazolil
ATE200760T1 (de) Formular das unerlaubtes lesen erkennen lässt, zur sicheren übermittlung von informationen
HK1069039A1 (en) Network zones
BR0315450A (pt) Circuito eletrônico à prova de violação para implantação de um dispositivo, dispositivo implementado com um circuito eletrônico à proca de violação, e, métodos de gerenciamento de dados de segurança para um dispositivo, para manter segurança de dados em relação a comunicação de rede entre um dispositivo de rede e um parceiro de comunicação externa, e para marcar conteúdo digital produzido por um dispositivo de produção de conteúdo.
BR0005192A (pt) Aparelho de processamento de dados, unidade terminal possuindo um meio de gravação não volátil fixável/destacável, e, processos de processamento de dados, e de transmissão de um aparelho de processamento de dados
ATE462697T1 (de) Bisaryl-sulfonamide
NO20054989D0 (no) 1,2,4-substituerte 1,2,3,4-tetrahydro og 1,2,dihydro-quinolin og 1,2,3,4-tetrahydro-quinoksalinderivater som CETP inhibitorer for behandlingen av aterosklerose og fedme
ATE472992T1 (de) Stabilisierung von körperpflegemittel und haushaltsmitteln
FI861995A (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 2-(4-benzoyl-1-piperidinyl)-1 -fenylalkanolderivat.
NZ585829A (en) Hydrolysis resistant organomodified trisiloxane ionic surfactant compositions and aqueous emulsion thereof
TR200201613T2 (tr) Antitümör tesirli 2-(1H-indol-3-il)-2-okso asetamidler
DE60007939D1 (de) Wäschewaschmaschine
BR9911422A (pt) Processo de tratamento de hipertensão pulmonar
FI972850A0 (fi) Optisesti vaalennettujen muovien käyttö paperin päällystyslietteiden vaalentamiseksi optisesti ja tällä tavoin optisesti vaalennettuja paperin päällystyslietteitä
BR0012072A (pt) Processo para o tratamento ou prevenção de vasoespasmo de enxerto coronário
BR9912000A (pt) Uso de derivados de tetraidropiridina (ou 4-hipropiperidina)- butilazóis na preparação de medicamento para tratamento de dor
DK293890D0 (da) 3-oe2,(4-arylpiperazin1-yl)-ethoxylaap-cymen, derivater deraf, som er ortho-, meta- og paramonosubstituerede eller -disubstituerede paa phenylringen, fremgangsmaade til fremstilling af saadanne derivater samt laegemidler, hvori forbindelserne er til stede som det aktive middel
Windley Sealing XML Security Gaps. Firewalls watch app traffic for trouble
SE0104108D0 (sv) Förfarande för återvinning av pyrolysvätskor
Kust Sodium Bromide
TR200000652T2 (tr) Dokümanlar için eğimli optik güvenlik elemanlarının yapılandırılması ve bu güvenlik elemanlarının kontrolü için geliştirilen bir tertibat ve bu güvenlik elemanları ve tertibatlarının uygulanması işlemi.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/07/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/06/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 22A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2728 DE 18/04/2023 POR TER SIDO INDEVIDA.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 27/06/2021